A number of other research analysts also recently issued reports on BAYN. UBS Group set a €130.00 ($151.16) price target on Bayer and gave the company a buy rating in a report on Thursday, June 7th. Sanford C. Bernstein set a €118.00 ($137.21) price target on Bayer and gave the company a buy rating in a report on Thursday, June 14th. Jefferies Financial Group set a €120.00 ($139.53) price target on Bayer and gave the company a buy rating in a report on Friday, June 15th. Citigroup set a €132.00 ($153.49) price target on Bayer and gave the company a buy rating in a report on Monday, June 18th. Finally, DZ Bank reaffirmed a buy rating on shares of Bayer in a report on Tuesday, June 19th. Seven equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of €99.11 ($115.25).
Shares of FRA:BAYN opened at €74.66 ($86.81) on Thursday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: Google Finance Portfolio
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.